Plain-English translation of NCT05392413 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why some people with advanced esophageal cancer respond well to PD-1 monoclonal antibody treatment while others don't. This study will collect blood samples from 200 patients before, during, and after receiving this medication combined with chemotherapy. By analyzing changes in immune cells in the blood, the researchers hope to create a simple test that can predict which patients will benefit most from this treatment.
Right now, doctors cannot easily predict which patients will respond to this medication—some people benefit greatly while others don't. A single blood test isn't reliable enough to guide treatment decisions. This study aims to solve that problem by combining multiple immune markers into one predictive tool, so doctors can better choose which patients should receive this treatment.
You likely qualify if…
You likely don't qualify if…
You will receive the medication (PD-1 monoclonal antibody) along with standard chemotherapy as your cancer treatment. Throughout your treatment, you will have blood draws before starting therapy, and at intervals during treatment to measure changes in your immune cells. Researchers will track how well the medication works for you and compare your blood findings to other patients' results to build the predictive tool.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Nanfang Hospital, Southern Medical University
Enrollment target
~200 participants
Started
August 2022
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Shuai Chu
Nanfang Hospital, Southern Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.